Today: 10 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

IBM Stock Rockets 28%: AI Boom, Quantum Breakthroughs & Big Deals Spark Rally

IBM Stock Rockets 28%: AI Boom, Quantum Breakthroughs & Big Deals Spark Rally

Recent Stock Rally Driven by AI and Quantum News IBM’s stock has rallied sharply in fall 2025. It closed around $279 on Oct 13 ts2.tech, just shy of its late-September peak near $296 ts2.tech. Investors point to IBM’s pivot to AI, cloud and quantum computing as catalysts. In late September, the company announced a first-of-its-kind quantum computing trial with HSBC, which used IBM’s quantum processor to improve bond-trading forecasts by 34% reuters.com. HSBC’s Philip Intallura said the trial is “a tangible example of how today’s quantum computers could solve a real-world business problem at scale” reuters.com. The news (Sept. 25)
18 October 2025
 ·  ·  ·  ·  · 
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high (tens of millions of shares), reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated
18 October 2025
 ·  ·  ·  ·  · 
Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

CSCO Stock Climbs on Strong Quarter: Cisco’s stock has steadily climbed in 2025, even as many tech peers swung wildly during the AI frenzy. As of mid‑October, CSCO is trading just below its year-high ts2.tech ts2.tech. Over the past week the stock added roughly 2% on investor optimism around recent announcements ts2.tech. Market observers note Cisco’s low volatility (beta <1) and broad support: shares have stayed above key moving averages (50-day ~$68, 200-day ~$65) ts2.tech. “Cisco’s stock has been a steady performer in 2025,” TechStock² (ts2.tech) notes, ~31% higher than a year ago ts2.tech. The company’s market cap is now
18 October 2025
 ·  ·  ·  ·  · 
New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

Key Stock Metrics: Metric Value (as of Oct 17, 2025) Closing Price $4.55 investing.com 1-Day Change +44.4% (vs $3.15 prev. close) stockanalysis.com Day’s Range $3.20 – $4.71 stockanalysis.com Volume (Oct 17) 33.82 million stockanalysis.com Market Cap ~$129.3 million investing.com 52-Week Range $0.32 – $12.29 stockanalysis.com AI Data Center Pivot Fuels Wild Rally New Era’s stock has rocketed in October thanks to its high-profile push into AI data centers. Mid-September it rebranded from New Era Helium to New Era Energy & Digital, emphasizing its shift into “energy-enabled” digital infrastructure ts2.tech. The company’s 50/50 joint venture, Texas Critical Data Centers (TCDC), is
18 October 2025
 ·  ·  ·  · 
MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

Stock Soars on Catalyst News MindMed’s stock has skyrocketed in recent weeks. After languishing in the single digits, MNMD climbed above $12 in late September and spiked to $13.09 on Oct. 14, its highest level in over a year ts2.tech marketbeat.com. The surge has pushed the stock roughly +68% year-to-date ts2.tech. Heavy trading volume accompanied the rise, as investors reacted to the latest clinical and regulatory news. (By Oct 17, shares were trading around $13.60 stockinvest.us.) This rally has made MindMed one of the year’s best-performing small-cap biotechs. Wall Street sentiment is strongly positive: MarketBeat notes MNMD has seven analyst
18 October 2025
 ·  ·  ·  ·  · 
Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

SPCE’s October Volatility: Surge and Selloff In mid-October 2025, Virgin Galactic’s stock was a top mover in the market. After languishing in the low-$3 range, SPCE shares rallied over 40% in early October on a wave of positive news ts2.tech. For example, on Oct. 16 alone the stock jumped about 6% intraday. Trading volume exploded as speculative traders piled in on hopes of new catalysts ts2.tech reuters.com. However, this enthusiasm was met by profit-taking almost immediately: by Oct. 17 the stock plunged 7.9%, erasing much of the gains and closing around $4.08 ts2.tech reuters.com. The volatile swings were driven by Virgin’s history
18 October 2025
 ·  ·  ·  ·  · 
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
 ·  ·  ·  ·  · 
Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

Indonesia’s abrupt pivot to Chinese fighters has captured global attention. Defense analysts say it underscores Jakarta’s insistence on strategic autonomy. “Foreign actors can spread disinformation, but at the end of the day, Indonesia buys what it chooses,” writes analyst Muhammad Zulfikar Rakhmat asiatimes.com. In practice, Jakarta is “quietly demonstrating that strategic autonomy is possible” – fielding the latest jets from East and West while balancing great-power pressures asiatimes.com. For now, Southeast Asian neighbors and global arms makers will be watching closely how this deal unfolds and how it reshapes the region’s airpower balance. Sources: Official statements and budget documents; reporting
18 October 2025
 ·  ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains (the S&P 500 and Nasdaq Composite were each up only ~0.5% that day investing.com). Deal Details: Under the Chugai
18 October 2025
 ·  ·  ·  ·  · 
Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Debt Restructure Sparks Stock Crash Beyond Meat’s brand remains visible to consumers, but behind the scenes its finances are in crisis. In mid-October 2025 the company announced an early settlement of its convertible debt exchange offer, triggering a historic market reaction. As Reuters reports, BYND shareholders are “agonizing” after the company offered existing bondholders new debt and stock in place of their $1.1 billion 2027 notes reuters.com globenewswire.com. With ~96.9% of noteholders participating, Beyond Meat will issue about $196.2 M in new 7.0% convertible notes (due 2030) plus a $12.5 M tender premium – roughly $208.7 M total – and 316.15 million new shares
18 October 2025
 ·  ·  ·  · 
Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Stock Surges on Q3 Results Liberty Energy’s logo (shown above) has been in the spotlight as the stock rallied on the latest earnings. On October 17, one day after Liberty’s Q3 report, the stock soared ~28% intraday, closing at $15.32 (vs. $11.94 the previous day) reuters.com ts2.tech. That move (adding about $3.4 per share of value overnight) came even though broader markets were relatively calm. Traders piled in on the “better-than-feared” outcome. By contrast, LBRT’s shares had been drifting lower for months; at one point earlier in Oct they were down over 40% on the year ts2.tech. Why the sudden
18 October 2025
 ·  ·  ·  · 
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is “Buy” (with average target ~$125) based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs (e.g. a PEPFAR-backed plan to deliver Yeztugo overseas), the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news
18 October 2025
 ·  ·  ·  · 
1 … 61 62 63 64 65 … 171
Go toTop